Pulmatrix (NASDAQ: PULM) Investor Presentation 9/5/2018
Pulmatrix Corporate Overview (2018.08) – final for website
Pulmatrix (NASDAQ: PULM) Investor Presentation
Healthcare
CytoDyn (OTC: CYDY) and Samsung BioLogics Formalize Manufacturing Partnership
INCHEON, South Korea, May 30, 2019 – CytoDyn Inc., (OTC: CYDY) a late stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications and Samsung BioLogics met at […]
CEO Interview
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) Creating “blockbuster” potential drugs, from deuterium chemistry tech
Get our FREE Newsletter! Discover Stocks with +1,000% Upside Potential! Thank you for subscribing. Something went wrong. Join over 100,000 investors and business leaders worldwide. Discover the Next Super Stock before the rest of […]
Healthcare
CytoDyn (OTC: CYDY) to Present New Data from Study of Investigational HIV Therapy Leronlimab (PRO 140), a Long-Acting, Single-Agent Maintenance Therapy at CROI 2019
VANCOUVER, Washington, Feb. 27, 2019 — CytoDyn Inc. (OTC.QB: CYDY), a late stage biotechnology company developing a novel humanized CCR5 monoclonal antibody for multiple therapeutic indications, today announced that data from its study of leronlimab […]